Articles related to Hematology/Oncology

The FDA granted Fast Track designation in September 2026 to multiple investigational oncology agents and one prostate cancer imaging strategy, highlighting continued regulatory support for therapies targeting high unmet needs across solid tumors and hematologic malignancies.

A patient with advanced follicular lymphoma described a prolonged diagnostic journey marked by evolving symptoms, initial alternative diagnoses, urgent treatment initiation, and the psychological challenges that continued long after active therapy began.

Tumor genomes may evolve during treatment as resistant subclones emerge under therapeutic pressure, prompting increasing use of comprehensive genomic profiling and serial ctDNA testing to inform ongoing precision oncology decisions.

Growing numbers of cancer survivors are prompting renewed discussion about how survivorship services should be delivered, with oncology and palliative care leaders emphasizing symptom management, quality of life, clinician training, and long-term support needs.

A patient with PNH and persistent anemia during ravulizumab therapy experienced improved hemoglobin after danicopan was added, while an extended infusion delay highlighted treatment-continuity challenges without establishing protection from interrupted C5 inhibition.

National Cancer Database data suggest that approximately half of prostate cancer focal therapy use from 2010 to 2023 occurred outside current guideline-supported settings, highlighting persistent gaps between clinical practice and available evidence.